WHO recommends that persons who have survived/recovered from filovirus disease be offered structured follow-up after discharge.
- Año
- 2026
- Institución
- World Health Organization
Recomendado a favor
Fuerte
Certeza de la evidencia
Moderada
Resultados: 1 - 10 de 873
Resultados: 1 - 10 de 873
WHO suggests that for patients with suspected or confirmed filovirus disease requiring initiation of vasopressors, peripheral intravenous catheters be used rather than central venous catheters.
- Año
- 2026
- Institución
- World Health Organization
Recomendado a favor
Condicional
Certeza de la evidencia
Muy baja
WHO recommends that for patients with suspected or confirmed filovirus disease requiring central venous access, ultrasound guided placement be used rather than non-ultrasound guided placement.
- Año
- 2026
- Institución
- World Health Organization
Recomendado a favor
Fuerte
Certeza de la evidencia
Moderada
WHO suggests against the use of tranexamic acid in patients with confirmed filovirus disease and haemorrhage.
- Año
- 2026
- Institución
- World Health Organization
Recomendado en contra
Condicional
Certeza de la evidencia
Muy baja
WHO recommends that patients with suspected or confirmed filovirus disease requiring a vasopressor be treated with norepinephrine rather than dopamine.
- Año
- 2026
- Institución
- World Health Organization
Recomendado a favor
Fuerte
Certeza de la evidencia
Moderada
WHO suggests for the use of presumptive broad-spectrum antibiotics in patients with confirmed filovirus disease in the presence of suspected sepsis or bacterial co-infection.
- Año
- 2026
- Institución
- World Health Organization
Recomendado a favor
Condicional
Certeza de la evidencia
Baja
WHO suggests patients with suspected or confirmed filovirus disease with ongoing gastrointestinal fluid losses and severe dehydrationa be treated with a protocolized intravenous fluid regimenb compared with no protocolized intravenous fluid regimen
- Año
- 2026
- Institución
- World Health Organization
Recomendado a favor
Condicional
Certeza de la evidencia
Baja
WHO recommends patients with suspected or confirmed filovirus disease with ongoing gastrointestinal fluid losses and some dehydrationa be treated with a protocolized oral rehydration regimen (e.g. WHO Plan B).
- Año
- 2026
- Institución
- World Health Organization
Recomendado a favor
Fuerte
Certeza de la evidencia
Moderada
WHO suggests for the use of tranexamic acid in patients with confirmed filovirus disease and postpartum haemorrhage.
- Año
- 2026
- Institución
- World Health Organization
Recomendado a favor
Condicional
Certeza de la evidencia
Baja
WHO recommends that Ervebo® should not be used outside of controlled research settings in response to the current Bundibugyo virus ( BDBV ) outbreak.
- Año
- 2026
- Institución
- World Health Organization
Recomendación en contexto de investigación
Solo en contextos de investigación
Certeza de la evidencia
Muy baja